Taiwan Biomedical Manufacturing Company (TBMC), which has the best chance in the domestic biotech industry to enter the international arena, will announce today (April 17) that the chairman will be Patrick Y. Yang, co-founder and vice chairman of National Resilience in the United States. Leveraging his extensive experience in high-tech manufacturing processes and abundant international connections, it is reported that TBMC's Series A funding has been oversubscribed 2-3 times and has attracted funding from the United States, Japan, Singapore, and other countries.
Established in 2023, TBMC aims to become the TSMC of biotechnology and aims to successfully transform within five years. In February of this year, TBMC formed a strategic alliance with National Resilience in the United States. In the first phase, TBMC will obtain licensing for National Resilience's five advanced processes in bioBiopharmceuticals, vaccines, mRNA nucleic acid drugs, cell therapy, and gene therapy, accelerating Taiwan's alignment with the global market in nucleic acid drugs.
Patrick Y. Yang stated that he grew up in Taiwan and has a deep affection for his homeland. He believes that the biotech industry is at a critical juncture in entering a new era. Amid the opportunities created by the U.S.-China trade war for Taiwan, he is eager to share his accumulated experience in manufacturing processes and network with the biotech industry to accelerate its entry into the international arena.
With the approval of Patrick Y. Yang and CEO David Chang, TBMC's team will begin factory construction, initiating the direction of construction, operation, and subsequent orders. The production base in the Hsinchu Biomedical Park is planned to be an 11-story building, with construction scheduled to commence this year, aiming for completion and production by 2027. Currently, the focus is on the top three contract manufacturing directions, including nucleic acid drugs, gene therapy drugs, and cell therapy drugs.
Patrick Y. Yang emphasized that the cooperation between National Resilience and TBMC can create significant benefits, with the alliance being "1 + 1 greater than 10." It is expected to achieve its goals by 2025. Specifically, the Hsinchu plant is expected to be completed and achieve GMP certification within two years. In the future, production capacity can be expanded to 2,000 liters, surpassing Samsung Biologics' capacity of over 10,000 liters with current technology and quality.
TBMC's seed fund has a paid-up capital of NT$3.44 billion, with the National Development Fund holding 29% of the shares (with a maximum of 40%). Originally estimated to raise NT$4.5 billion to NT$4.6 billion in Series A funding from private investors, the fundraising case has caused a stir even before its official launch. The intended subscription has exceeded the target amount, with international funds from the United States, Japan, Singapore, and other countries joining. It is reported that the excess funds exceed NT$5 billion. Therefore, the board of directors is considering whether to reduce the National Development Fund's shareholding or return the excess funds to shareholders in proportion.
Resource (Mandarin):
